Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00989261 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 333
- Enrollment target
NCT00989261 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 333 participants.
The verdict
NCT00989261, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 333 participants
- Enrollment target
Study Summary
AC220 will be administered as a once daily oral solution given continuously as 28-day treatment cycles, without any rest periods, until disease progression, relapse, intolerance to the drug, or elective allogeneic hematopoietic stem cell transplantation (HSCT).
Interventions
- DRUG Compound AC220
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 333 participants |
| Start Date | 2009-11 |
| Est. Completion | 2014-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00989261
The ClinicalTrials.gov registry entry for NCT00989261 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 333 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Compound AC220 is the first listed.
NCT00989261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00989261 about?
NCT00989261 is a clinical study titled "Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)". AC220 will be administered as a once daily oral solution given continuously as 28-day treatment cycles, without any rest periods, until disease progression, relapse, intolerance to the drug, or elective allogeneic hematopoietic stem cell transplantation (HSCT).
What is the current status of trial NCT00989261?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 333 participants. The study started on 2009-11. Estimated completion is 2014-12-31.
What interventions are being tested in trial NCT00989261?
The interventions under investigation include: Compound AC220 (DRUG).
Who is sponsoring clinical trial NCT00989261?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.